🇺🇸 FDA
Patent

US 11225664

Modulation of angiopoietin-like 3 expression

granted A61PA61P1/16A61P3/00

Quick answer

US patent 11225664 (Modulation of angiopoietin-like 3 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P1/16, A61P3/00, A61P3/04, A61P3/06